论文部分内容阅读
目的:探讨甘精胰岛素联合格列吡嗪在治疗2型糖尿病中的应用价值。方法:选取2011年3月-2013年3月我院收治的2型糖尿病患者140例,按不同治疗方式随机分为对照组(给予“诺和灵30R+格列吡嗪”治疗)和实验组(给予“甘精胰岛素+格列吡嗪”治疗),就两组患者治疗前和治疗8周后的三餐前、三餐2h后的血糖水平和空腹C肽、餐后2hC肽以及糖化血红蛋白(HbAlc)水平进行综合比较。结果:经治疗8周后,两组患者血糖水平较治疗前均有明显下降,但实验组患者下降幅度较对照组更明显(p<0.05);实验组患者经治疗8周后C肽水平及HbAlc改善明显好于对照组患者(p<0.05)。结论:甘精胰岛素联合格列吡嗪治疗2型糖尿病不仅能有效控制血糖,更能够有效保护患者胰岛B细胞分泌功能,值得临床推广。
Objective: To investigate the clinical value of glargine combined with glipizide in the treatment of type 2 diabetes mellitus. Methods: Forty-two patients with type 2 diabetes mellitus admitted to our hospital from March 2011 to March 2013 were randomly divided into control group (given “Norvard 30R + Glipizide ”) and experiment (Given “insulin glargine + glipizide ” treatment), two groups of patients before and after treatment for 8 weeks before the three meals, three meals after 2h blood glucose levels and fasting C-peptide, 2h postprandial peptide And HbAlc levels were compared comprehensively. Results: After 8 weeks of treatment, the blood sugar levels of both groups were significantly decreased compared with those before treatment, but the decline rate of the experimental group was more obvious than that of the control group (p <0.05). After 8 weeks of treatment, the C-peptide level and HbAlc improved significantly better than the control group patients (p <0.05). Conclusion: Glargine and glipizide in type 2 diabetes not only can effectively control blood sugar, but also can effectively protect the pancreatic islet B cell secretory function of patients, worthy of clinical promotion.